Abstract
Purpose
Epithelial ovarian cancers either arise directly from Mullerian-type epithelium or acquire Mullerian characteristics in the course of neoplastic transformation. The anti-Mullerian hormone (AMH) causes regression of Mullerian structures during fetal development in males and has been shown to inhibit the growth of epithelial ovarian cancer. Therefore, we hypothesized that pre-diagnostic serum concentrations of AMH are inversely associated with risk of invasive serous ovarian cancer.
Methods
A case–control study (107 cases, 208 controls) was nested within the population-based Finnish Maternity Cohort (1986–2007). The sample donated during the first trimester of the last pregnancy preceding cancer diagnosis of the case subjects was selected for the study. For each case, two controls, matched on age and date at sampling, as well as parity at sampling and at cancer diagnosis were selected. AMH was measured by a second-generation AMH ELISA. Conditional logistic regression was used to compute odds ratios (OR) and 95 % confidence intervals (CI) for invasive serous ovarian cancer associated with AMH concentrations.
Results
Overall AMH concentrations were not associated with risk of invasive serous ovarian cancer (OR 0.93; 95 % CI 0.49–1.77 for top vs. bottom tertile, P trend = 0.83). In women older than the median age at sampling (32.7 years), a doubling of AMH was associated with decreased risk (OR 0.69; 95 % CI 0.49–0.96), whereas an increased risk (OR 1.64; 95 % CI 1.06–2.54) was observed in younger women, P homogeneity = 0.002.
Conclusions
In this first prospective investigation, risk of invasive serous ovarian cancer was not associated with pre-diagnostic AMH concentrations overall; however, the association may depend on age at AMH measurement.
Similar content being viewed by others
References
Dubeau L (2008) The cell of origin of ovarian epithelial tumours. Lancet Oncol 9(12):1191–1197
Scully RE (1977) Ovarian tumors. A review. Am J Pathol 87(3):686–720
Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22(2):255–288
MacLaughlin DT, Donahoe PK (2010) Mullerian inhibiting substance/anti-mullerian hormone: a potential therapeutic agent for human ovarian and other cancers. Future Oncol 6(3):391–405
Weenen C, Laven JS, Von Bergh AR et al (2004) Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 10(2):77–83
Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH (2011) A validated model of serum anti-mullerian hormone from conception to menopause. PLoS ONE 6(7):e22024
La Marca A, Sighinolfi G, Giulini S et al (2010) Normal serum concentrations of anti-Mullerian hormone in women with regular menstrual cycles. Reprod Biomed Online 21(4):463–469
Nelson SM, Stewart F, Fleming R, Freeman DJ (2010) Longitudinal assessment of antimullerian hormone during pregnancy-relationship with maternal adiposity, insulin, and adiponectin. Fertil Steril 93(4):1356–1358
Lutterodt M, Byskov AG, Skouby SO, Tabor A, Yding AC (2009) Anti-Mullerian hormone in pregnant women in relation to other hormones, fetal sex and in circulation of second trimester fetuses. Reprod Biomed Online 18(5):694–699
Meirelles K, Benedict LA, Dombkowski D et al (2012) Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc Natl Acad Sci USA 109(7):2358–2363
Bakkum-Gamez JN, Aletti G, Lewis KA et al (2008) Mullerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers. Gynecol Oncol 108(1):141–148
Song JY, Chen KY, Kim SY et al (2009) The expression of Mullerian inhibiting substance/anti-Mullerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia. Int J Oncol 34(6):1583–1591
Chang HL, Pieretti-Vanmarcke R, Nicolaou F et al (2011) Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines. Gynecol Oncol 120(1):128–134
Koskela P, Anttila T, Bjorge T et al (2000) Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 85(1):35–39
Teppo L, Pukkala E, Lehtonen M (1994) Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 33(4):365–369
Cleveland WS, Loader C (1996) Smoothing by Local Regression: Principles and Methods. In: Härdle W, Schimek MG (eds) Statistical theory and computational aspects of smoothing, 1st edn. Physica-Verlag, Heidelberg, pp 10–49
Cohen J, Cohen P, West SG, Aiken LS (2003) Multiple Regression/Correlation with two or more independent variables. Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences, 3rd edn. Lawrence Erlbaum Associates, Mahwah, NJ, pp 64–100
Whitehead A, Whitehead J (1991) A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 10(11):1665–1677
Josso N (2008) Professor Alfred Jost: the builder of modern sex differentiation. Sex Dev 2(2):55–63
Picard JY, Josso N (1984) Purification of testicular anti-Mullerian hormone allowing direct visualization of the pure glycoprotein and determination of yield and purification factor. Mol Cell Endocrinol 34(1):23–29
Grynnerup AG, Lindhard A, Sorensen S (2012) The role of anti-Mullerian hormone in female fertility and infertility—an overview. Acta Obstet Gynecol Scand 91(11):1252–1260
Teixeira J, Maheswaran S, Donahoe PK (2001) Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr Rev 22(5):657–674
Fanchin R, Taieb J, Lozano DH, Ducot B, Frydman R, Bouyer J (2005) High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod 20(4):923–927
Dorgan JF, Spittle CS, Egleston BL, Shaw CM, Kahle LL, Brinton LA (2010) Assay reproducibility and within-person variation of Mullerian inhibiting substance. Fertil Steril 94(1):301–304
van Rooij I, Broekmans FJ, Scheffer GJ et al (2005) Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 83(4):979–987
Baird DD, Steiner AZ (2012) Anti-Mullerian hormone: a potential new tool in epidemiologic studies of female fecundability. Am J Epidemiol 175(4):245–249
La Marca A, Spada E, Grisendi V et al (2012) Normal serum anti-Mullerian hormone levels in the general female population and the relationship with reproductive history. Eur J Obstet Gynecol Reprod Biol 163(2):180–184
Dolleman M, Verschuren WM, Eijkemans MJ et al (2013) Reproductive and lifestyle determinants of anti-Mullerian hormone in a large population-based study. J Clin Endocrinol Metab 98(5):2106–2115
Plante BJ, Cooper GS, Baird DD, Steiner AZ (2010) The impact of smoking on antimullerian hormone levels in women aged 38 to 50 years. Menopause 17(3):571–576
Smith ER, Xu XX (2008) Ovarian ageing, follicle depletion, and cancer: a hypothesis for the aetiology of epithelial ovarian cancer involving follicle depletion. Lancet Oncol 9(11):1108–1111
Durlinger AL, Visser JA, Themmen AP (2002) Regulation of ovarian function: the role of anti-Mullerian hormone. Reproduction 124(5):601–609
Visser JA, Durlinger AL, Peters IJ et al (2007) Increased oocyte degeneration and follicular atresia during the estrous cycle in anti-Mullerian hormone null mice. Endocrinology 148(5):2301–2308
Masse V, Ferrari P, Boucoiran I, Delotte J, Isnard V, Bongain A (2011) Normal serum concentrations of anti-Mullerian hormone in a population of fertile women in their first trimester of pregnancy. Hum Reprod 26(12):3431–3436
Lie Fong S, Visser JA, Welt CK et al (2012) Serum anti-mullerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab 97(12):4650–4655
Kristensen SL, Ramlau-Hansen CH, Andersen CY et al (2012) The association between circulating levels of antimullerian hormone and follicle number, androgens, and menstrual cycle characteristics in young women. Fertil Steril 97(3):779–785
Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS (2005) Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 20(7):1820–1826
Moorman PG, Calingaert B, Palmieri RT et al (2008) Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol 167(9):1059–1069
Acknowledgments
This work was supported by research grants from the US National Cancer Institute (Grant R01 CA120061) and the Lion’s Cancer Foundation at Umeå University, Sweden.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schock, H., Lundin, E., Vääräsmäki, M. et al. Anti-Mullerian hormone and risk of invasive serous ovarian cancer. Cancer Causes Control 25, 583–589 (2014). https://doi.org/10.1007/s10552-014-0363-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-014-0363-9